Clinical Trial Update: Personalized PRRT of Neuroendocrine Tumors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update for personalized peptide receptor radionuclide therapy (PRRT) in neuroendocrine tumors, currently active but not recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carcinoid Tumor
• Neuroendocrine Tumor

Snippet

Sponsor: CHU de Quebec-Universite Laval | Conditions: Neuroendocrine Tumors, Carcinoid Tumor | Phase 2 | Status: ACTIVE_NOT_RECRUITING